Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: Decreasing dosage does not alter serum IgG levels

Journal of Clinical Immunology

Volumn 30, Issue 4, 2010, Pages 602-606

  Thépot, Sylvain ^a   Malphettes, Marion ^a   Gardeur, Anaëlle ^a   Galicier, Lionel ^a   Asli, Bouchra ^a   Karlin, Lionel ^a   Gérard, Laurence ^a   Laumont, Richard ^a   Doize, Marie Laure ^a   Arnulf, Bertrand ^a   Fieschi, Claire ^a   Bengoufa, Djaouïda ^a   Oksenhendler, Eric ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Primary immune deficiency; Subcutaneous immunoglobulin replacement; Therapy

Indexed keywords

GAMMANORM; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; SUBCUVIA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG SAFETY; DRUG SELF ADMINISTRATION; FEMALE; HOME CARE; HOSPITALIZATION; HUMAN; HYPER IGM SYNDROME; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; LONGITUDINAL STUDY; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIMARY HYPOGAMMAGLOBULINEMIA; PRIORITY JOURNAL; SANFILIPPO SYNDROME; SUBSTITUTION THERAPY; X LINKED AGAMMAGLOBULINEMIA; X LINKED LYMPHOPROLIFERATIVE DISEASE; AGAMMAGLOBULINEMIA; BLOOD; PASSIVE IMMUNIZATION; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

AGAMMAGLOBULINEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES;

EID: 77956266842     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9417-2     Document Type: Article

References (22)

1. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34-48.
2. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46:1547-54.
3. Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85:193-202.
4. Morell A. Clinical relevance of IgG subclass deficiencies. Ann Biol Clin (Paris). 1994;52:49-52.
5. Cunningham-Rundles C, Siegal FP, Smithwick EM, Lion-Boulé A, Cunningham-Rundles S, O'Malley J, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984;101:435-9.
6. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109:1001-4.
7. Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A, Movahedi M, Gharagozlou M, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect. 2006;39:114-20.
8. Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149:410-23.
9. Gardulf A, Andersen V, Björkander J, Ericson D, Frøland SS, Gustafson R, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365-9.
10. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162-6.
11. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:434-42.
12. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105-16.
13. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94-100.
14. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008;28:803-19.
15. Waniewski J, Gardulf A, Hammarström L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol. 1994;14:90
16. Steady state.
17. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group. Safety and efficacy of selfadministered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265-73.
18. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112:1-7.
19. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New Engl J Med. 1999;340:227-8.
20. Gustafson R, Gardulf A, Hansen S, Leibl H, Engl W, Lindén M, et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol. 2008;152:274-9.
21. Radinsky S, Bonagura V. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol. 2003;112:630-33.
22. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J Clin Immunol. 2006;26:177-85.